1. 1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Wakelee, H; Reckamp, K L; Leal, T A; Patel, S P; Blumenschein, G; Shum, E; Nieva, J; Oxnard, G; Sanborn, R E; Waqar, S; Zeman, K; Dukart, G; Harrow, K; Liang, C; Holzhausen, A; Horn, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1500TiPeXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. (23rd October 2018) Authors: Horn, L; Wu, Y-L; Reck, M; Wakelee, H; Liang, C; Harrow, K; Oertel, V; Mok, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1862PA phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors. (23rd October 2018) Authors: Bendell, J; Moore, K N; Patel, M R; Chua, C; Arkenau, H-T; Dukart, G; Harrow, K; Liang, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗